Barbara Bodinier

Barbara Bodinier

Auto-generated profile, based on publicly available information

Barbara Bodinier

School of Public Health, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSaredo Said
Saredo Said
RPRaha Pazoki
Raha Pazoki
VKVille Karhunen
Ville Karhunen
UVUrmo Võsa
Urmo Võsa
SLSymen Ligthart
Symen Ligthart
ADAbbas Dehghan
Abbas Dehghan
Chronic low-grade inflammation is linked to a multitude of chronic diseases. We report the largest genome-wide association study (GWAS) on C-reactive protein (CRP), a marker of systemic inflammation, in UK Biobank participants (N = 427,367, European descent) and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (total N = 575,531 European descent). We identify 266 independent loci, of which 211 are not previously reported. Gene-set analysis highlighted 42 gene sets associated with CRP levels (p ≤ 3.2 ×10−6) and tissue expression analysis indicated a strong association of CRP related genes with liver and whole blood gene expression. Phenome-wide association study identified 27 clinical outcomes associated with genetically determined CRP and subsequent Mendelian randomisation analyses supported a causal association with schizophrenia, chronic airway obstruction and prostate cancer. Our findings identified genetic loci and functional properties of chronic low-grade inflammation and provided evidence for causal associations with a range of diseases.

25 March 2022 in Science
Verified
Journal Article
Open access
PEPaul Elliott
Paul Elliott
BBBarbara Bodinier
Barbara Bodinier
OEOliver Eales
Oliver Eales
HWHaowei Wang
Haowei Wang
DHDavid Haw
David Haw
CDChristl A Donnelly
Christl A Donnelly
The unprecedented rise in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections during December 2021 was concurrent with rapid spread of the Omicron variant in England and globally. We analyzed the prevalence of SARS-CoV-2 and its dynamics in England from the end of November to mid-December 2021 among almost 100,000 participants in the REACT-1 study. Prevalence was high with rapid growth nationally and particularly in London during December 2021, with an increasing proportion of infections due to Omicron. We observed large decreases in swab positivity among mostly vaccinated older children (12 to 17 years) relative to unvaccinated younger children (5 to 11 years), and in adults who received a third (booster) vaccine dose versus two doses. Our results reinforce the importance of vaccination and booster campaigns, although additional measures have been needed to control the rapid growth of the Omicron variant.

3 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMatthias Wielscher
Matthias Wielscher
PMPooja R. Mandaviya
Pooja R. Mandaviya
BKBrigitte Kuehnel
Brigitte Kuehnel
RJRoby Joehanes
Roby Joehanes
RMRima Mustafa
Rima Mustafa
MJMarjo-Riitta Järvelin
Marjo-Riitta Järvelin
We performed a multi-ethnic Epigenome Wide Association study on 22,774 individuals to describe the DNA methylation signature of chronic low-grade inflammation as measured by C-Reactive protein (CRP). We find 1,511 independent differentially methylated loci associated with CRP. These CpG sites show correlation structures across chromosomes, and are primarily situated in euchromatin, depleted in CpG islands. These genomic loci are predominantly situated in transcription factor binding sites and genomic enhancer regions. Mendelian randomization analysis suggests altered CpG methylation is a consequence of increased blood CRP levels. Mediation analysis reveals obesity and smoking as important underlying driving factors for changed CpG methylation. Finally, we find that an activated CpG signature significantly increases the risk for cardiometabolic diseases and COPD.

11 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMatthew Whitaker
Matthew Whitaker
JEJoshua Elliott
Joshua Elliott
BBBarbara Bodinier
Barbara Bodinier
WBWendy Barclay
Wendy Barclay
HWHelen Ward
Helen Ward
PEPaul Elliott
Paul Elliott
Infection with SARS-CoV-2 virus is associated with a wide range of symptoms. The REal-time Assessment of Community Transmission −1 (REACT-1) study monitored the spread and clinical manifestation of SARS-CoV-2 among random samples of the population in England from 1 May 2020 to 31 March 2022. We show changing symptom profiles associated with the different variants over that period, with lower reporting of loss of sense of smell or taste for Omicron compared to previous variants, and higher reporting of cold-like and influenza-like symptoms, controlling for vaccination status. Contrary to the perception that recent variants have become successively milder, Omicron BA.2 was associated with reporting more symptoms, with greater disruption to daily activities, than BA.1. With restrictions lifted and routine testing limited in many countries, monitoring the changing symptom profiles associated with SARS-CoV-2 infection and effects on daily activities will become increasingly important.

20 August 2020 in International Journal of Epidemiology
Verified
Journal Article
Open access
MCMarc Chadeau-Hyam
Marc Chadeau-Hyam
BBBarbara Bodinier
Barbara Bodinier
JEJoshua Elliott
Joshua Elliott
MWMatthew D Whitaker
Matthew D Whitaker
ITIoanna Tzoulaki
Ioanna Tzoulaki
PEPaul Elliott
Paul Elliott
Background: The recent COVID-19 outbreak has generated an unprecedented public health crisis, with millions of infections and hundreds of thousands of deaths worldwide. Using hospital-based or mortality data, several COVID-19 risk factors have been identified, but these may be confounded or biased.Methods: Using SARS-CoV-2 infection test data (n = 4509 tests; 1325 positive) from Public Health England, linked to the UK Biobank study, we explored the contribution of demographic, social, health risk, medical and environmental factors to COVID-19 risk. We used multivariable and penalized logistic regression models for the risk of (i) being tested, (ii) testing positive/negative in the study population and, adopting a test negative design, (iii) the risk of testing positive within the tested population.Results: In the fully adjusted model, variables independently associated with the risk of being tested for COVID-19 with odds ratio >1.05 were: male sex; Black ethnicity; social disadvantage (as measured by education, housing and income); occupation (healthcare worker, retired, unemployed); ever smoker; severely obese; comorbidities; and greater exposure to particulate matter (PM) 2.5 absorbance. Of these, only male sex, non-White ethnicity and lower educational attainment, and none of the comorbidities or health risk factors, were associated with testing positive among tested individuals.Conclusions: We adopted a careful and exhaustive approach within a large population-based cohort, which enabled us to triangulate evidence linking male sex, lower educational attainment and non-White ethnicity with the risk of COVID-19. The elucidation of the joint and independent effects of these factors is a high-priority area for further research to inform on the natural history of COVID-19.

24 June 2022 in Science
Verified
Journal Article
Open access
PEPaul Elliott
Paul Elliott
OEOliver Eales
Oliver Eales
NSNicholas Steyn
Nicholas Steyn
DTDavid Tang
David Tang
BBBarbara Bodinier
Barbara Bodinier
MCMarc Chadeau-Hyam
Marc Chadeau-Hyam
Rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has led to record-breaking incidence rates around the world. The Real-time Assessment of Community Transmission-1 (REACT-1) study has tracked SARS-CoV-2 infection in England using reverse transcription polymerase chain reaction (RT-PCR) results from self-administered throat and nose swabs from randomly selected participants aged 5 years and older approximately monthly from May 2020 to March 2022. Weighted prevalence in March 2022 was the highest recorded in REACT-1 at 6.37% ( N = 109,181), with the Omicron BA.2 variant largely replacing the BA.1 variant. Prevalence was increasing overall, with the greatest increase in those aged 65 to 74 years and 75 years and older. This was associated with increased hospitalizations and deaths, but at much lower levels than in previous waves against a backdrop of high levels of vaccination.